Renal toxicities associated with pembrolizumab-Reference-Cited by-同舟云学术

Renal toxicities associated with pembrolizumab

Published:2018-11-09 Issue:1 Volume:12 Page:81-88
ISSN:2048-8505
Container-title:Clinical Kidney Journal
language:en
Short-container-title:

Author:

Izzedine Hassan¹²,Mathian Alexis³,Champiat Stephane⁴,Picard Cécile⁵^ORCID,Mateus Christine⁶,Routier Emilie⁷,Varga Andrea⁴,Malka David⁸,Leary Alexandra⁹,Michels Judith⁹,Michot Jean-Marie⁴,Marabelle Aurélien⁴,Lambotte Olivier¹⁰,Amoura Zahir³,Soria Jean-Charles⁴,Kaaki Sihem¹¹,Quellard Nathalie¹¹,Goujon Jean-Michel¹¹,Brocheriou Isabelle⁵

Affiliation:

1. Department of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, Paris, France

2. UPEC (Université Paris Est Créteil), INSERM U955, Institut Mondor de Recherche Biomédicale (IMRB), Equipe, Créteil, France

3. Department of Internal Medicine, Pitie-Salpetriere Hospital, Paris, France

4. Drug Development Department (DITEP), Gustave Roussy, Villejuif, France

5. Department of Pathology, Pitie-Salpetriere Hospital, Paris, France

6. Department of Supportive Care, Gustave Roussy, Villejuif, France

7. Department of Medical Oncology, Dermatology Unit, Gustave Roussy, Villejuif, France

8. Department of Medical Oncology, Gastrointestinal Cancer Group, Gustave Roussy, Villejuif, France

9. Department of Medical Oncology, Gynecology Unit, Gustave Roussy, Villejuif, France

10. Department of Internal Medicine and Clinical Immunology, Bicetre University Hospital, Le Kremlin Bicêtre, France

11. Departement of Pathology, Electron Microscopy Unit, CHU Poitiers, Poitiers, France

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ckj/article-pdf/12/1/81/27721453/sfy100.pdf

Reference48 articles.

1. Immune checkpoint inhibitors in challenging populations;Johnson;Cancer,2017

2. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study;Lynch;J Clin Oncol,2012

3. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (ca184–043): a multicentre, randomised, double-blind, Phase 3 trial;Kwon;Lancet Oncol,2014

4. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy;Eggermont;N Engl J Med,2016

5. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in japanese patients with non-small-cell lung cancer;Horinouchi;Invest New Drugs,2015

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor–associated nephritis—treatment standard;Nephrology Dialysis Transplantation;2024-08-13

2. Bibliometric and visual analysis of immunisation associated with acute kidney injury from 2003 to 2023;Frontiers in Pharmacology;2024-07-01

3. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study;Biomolecules and Biomedicine;2024-06-25

4. Predominant CD8⁺ cell infiltration and low accumulation of regulatory T cells in immune checkpoint inhibitor‐induced tubulointerstitial nephritis;Pathology International;2024-04-18

5. Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib;Clinical Genitourinary Cancer;2024-04